Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study

Conditions:   Neuroendocrine Tumor;   Anaplastic Thyroid Cancer;   Adenocarcinoma;   Pheochromocytoma;   Paraganglioma Intervention:   Drug: Cabozantinib 40 mg Sponsors:   Grupo Espanol de Tumores Neuroendocrinos;   Ipsen;   Roche Pharma AG Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

ConclusionsWhile several CPGs are shared across patients, many pathogenic variants are found to be ancestry-specific and trigger somatic effects. Studies using larger cohorts of diverse ancestries are required to pinpoint ancestry-specific genetic predisposition and inform genetic screening strategies.
Source: Genome Medicine - Category: Genetics & Stem Cells Source Type: research
Conditions:   Neuroendocrine Tumor;   Anaplastic Thyroid Cancer;   Adenocarcinoma;   Pheochromocytoma;   Paraganglioma Intervention:   Drug: Cabozantinib 40 mg Sponsors:   Grupo Espanol de Tumores Neuroendocrinos;   Ipsen;   Roche Pharma AG Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Immunohistochemistry represents an indispensable complement to an epidemiology and morphology-driven approach to tumor diagnosis and site of origin assignment. This review reflects the state of my current practice, based on 15-years’ experience in Pathology and a deep-dive into the literature, always striving to be better equipped to answer the age old questions, “What is it, and where is it from?” The tables and figures in this manuscript are the ones I “pull up on the computer” when I am teaching at the microscope and turn to myself when I am (frequently) stuck. This field is so exciting bec...
Source: Advances in Anatomic Pathology - Category: Pathology Tags: Review Articles Source Type: research
1399Introduction: Somatostatin receptor (SSTR) targeting peptide receptor radiotherapy (PRRT) has been successfully introduced to the clinic, treating well-differentiated neuroendocrine tumor (NET) patients. Although SSTR is a promising theranostics target, the indication is limited to typical NET. Thus, broadening the scope of current clinical application is necessary. Here, we analyzed the clinical and genetic portraits related to SSTR expression across 9962 subjects representing 32 cancers. Methods: SSTR expression levels were assessed by RNA-seq data of the Cancer Genome Atlas. As the major target of PRRT is SSTR subty...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Oncology, Basic and Translational (Basic Science) Posters Source Type: research
Yi He†, Wenyong Long† and Qing Liu* Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China Super-enhancers (SEs) refer to large clusters of enhancers that drive gene expressions. Recent data has provided novel insights in elucidating the roles of SEs in many diseases, including cancer. Many mechanisms involved in tumorigenesis and progression, ranging from internal gene mutation and rearrangement to external damage and inducement, have been demonstrated to be highly associated with SEs. Moreover, translocation, formation, deletion, or duplication of SEs themselves co...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Adenocarcinoma | Brain | Cancer | Cancer & Oncology | Neurology | Paraganglioma | Pheochromocytoma | Research | Study